IGKV2-30

Across TCGA pan-cancer cohorts, IGKV2-30 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGKV2-30 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGKV2-30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV2-30 expression acts as an unfavorable survival marker.

LUAD and LIHC are the cancer types where IGKV2-30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	31	view →
LIHC	OS	Median	All	0.061	0.783	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGKV2-30–LUAD (OS)

Open the LUAD breakdown →